Gastroenterology
Pioglitazone prevents hepatic steatosis in animal models
Published in Hepatitis Weekly, April 5th, 2004
According to a study from Japan, "non-alcoholic steatohepatitis (NASH) may progress to liver cirrhosis, and NASH patients with liver cirrhosis have a risk of development of hepatocellular carcinoma. Peroxisome proliferator-activated receptor (PPAR) gamma ligand has recently been reported to have improved the condition of patients with NASH. The aim of this study was to investigate whether pioglitazone, a PPARgamma ligand, has any influence on the animal model of NASH as well as isolated hepatic stellate cells."
"In vivo, the effects of pioglitazone were examined using the choline-deficient...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-04-05)
More Articles from Hepatitis Weekly
- Infection Control
A critical juncture for hemodialysis-related HCV passage is saline flushing - Chronic Hepatitis C
The ribavirin prodrug viramidine has proven safe in healthy volunteers - Diagnostics
Non-radioactive labeled hepatitis B virus probes are sensitive and inexpensive - Gastroenterology
Microarray distinguishes the molecular signatures of hepatocellular carcinomas - Viral Genomics
Hepatitis delta virus probably harbors at least seven major clades - Breast Cancer
Lamivudine helps keep HBV at bay during cancer chemotherapy - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
